Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1861-1880 of 3,900 trials

Takotsubo Syndrome: Cyclosporine A Treatment Study

We are investigating whether cyclosporine A can help reduce heart damage in patients with Takotsubo syndrome compared to a placebo. This study aims to improve treatment options for this heart condition.

Healthy Participants>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesCardiologyInternal Medicine

Advanced Prostate Cancer: Debio 4228 Study

We are testing a new medication, Debio 4228, to see if it effectively lowers hormone levels in men with advanced prostate cancer. The study will also look at how well the medication is tolerated and its safety profile.

Advanced Prostate Cancer6-12 monthsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Treatment-Resistant PTSD: Mifepristone Study

We are investigating whether mifepristone can help reduce symptoms in people with treatment-resistant PTSD. This study compares its effects to a placebo to see if it offers better relief.

Post-traumatic Stress Disorder≤3 monthsEfficacy phase (II)Standard MedicinesPsychiatry

Simvastatin for Primary Sclerosing Cholangitis (PSC)

We are studying whether simvastatin can help people with PSC live longer without serious complications like bile duct cancer or the need for a transplant. We will also examine its effects on disease markers and symptoms.

Primary Sclerosing Cholangitis>2 yearsEfficacy phase (II)Standard MedicinesHepatologyOncology

Ampullary Adenocarcinoma: mFOLFIRINOX vs. Gemcitabine or Capecitabine

We are studying whether a combination chemotherapy can improve survival rates for patients after surgery for ampullary adenocarcinoma. The trial also looks at quality of life and side effects compared to standard treatments.

Ampullary Adenocarcinoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Narcolepsy: Safety Study of Lu AH69593

We are testing a new medication to see how safe it is for healthy adults and those with narcolepsy. This study will help us understand how well the medication is tolerated.

Narcolepsy1-2 yearsSafety phase (I)Internal MedicineNeurology

Ovarian and Lung Cancer: TUB-040 Treatment Study

We are investigating a new antibody-guided drug for patients with therapy-resistant ovarian or lung cancer. The study aims to assess its safety and how well it works compared to existing treatments.

Platinum-Resistant High-Grade Ovarian Cancer and Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementGynecology and ObstetricsOncologyPulmonology

Obsessive-Compulsive Disorder: Pramipexole Treatment Study

We are investigating whether pramipexole can improve treatment outcomes for individuals with resistant OCD. The study will also assess the safety of this medication and its effects on brain function.

Obsessive-Compulsive Disorder (OCD)6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Denosumab for Fibrous Dysplasia and McCune-Albright Syndrome

We are studying whether Denosumab can help reduce pain and improve quality of life for adults with Fibrous Dysplasia and McCune-Albright Syndrome. The trial will also look at its effects on mobility and bone health.

Fibrous Dysplasia/McCune-Albright Syndrome1-2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

B-Cell Blood Cancers: AZD5492 Treatment Study

We are investigating whether AZD5492 is safe and effective for adults with relapsed or refractory B-cell malignancies, both on its own and with other cancer treatments.

B-Cell Malignancies>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Chronic Myelomonocytic Leukemia: New Treatment Combination Study

We are testing a combination of azacitidine, venetoclax, and tagraxofusp for patients with higher-risk chronic myelomonocytic leukemia. The study aims to evaluate how well this treatment works and its safety.

Chronic Myelomonocytic Leukemia1-2 yearsEfficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesHematologyOncology

Parkinson’s Disease: RO7568282 Safety Study

We are testing a new drug, RO7568282, to see if it is safe for healthy people and those with Parkinson’s disease. This study will help us understand its effects on the body.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Calcium Absorption: Glycocholate and Butyrate Study

We are testing the safety and tolerability of glycocholate and butyrate in healthy women who have undergone Roux-en-Y gastric bypass. This study aims to see if these substances can help improve calcium absorption.

Postoperative Obesity≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Ribociclib for Cancer Patients: Continued Access Study

We are offering patients who previously benefited from ribociclib the chance to continue treatment. This study also aims to collect important safety information about ribociclib alone or with other investigational therapies.

Advanced CancerSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Crizotinib Safety Study for Cancer Patients

We are monitoring the safety of crizotinib for individuals who have participated in earlier studies. This research aims to ensure the continued well-being of patients using this treatment.

Solid TumorMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Senicapoc for Progressive Fibrotic Interstitial Lung Disease

We are studying whether Senicapoc can help slow the progression of lung disease in patients with progressive fibrotic ILD. This trial compares its effects to a placebo alongside standard care.

Interstitial Pulmonary Fibrosis6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesPulmonology

Non-Small Cell Lung Cancer: Immunotherapy and Chemotherapy Study

We are studying a treatment combining immunotherapy, chemotherapy, and radiotherapy for patients with newly diagnosed non-small cell lung cancer that has spread to a few other areas. The aim is to see if this approach helps patients live longer without their cancer worsening.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Triple Negative Breast Cancer: Imatinib Study

We are investigating whether Imatinib can convert triple negative breast cancer into a more treatable ER-positive type. The study also examines the safety of the drug and its effects on related cancer markers.

Triple Negative Breast CancerPrimary Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesOncology

CD30-Positive Lymphoma: Brentuximab Imaging Study

We are investigating how a drug called Brentuximab distributes in the body of patients with CD30-positive lymphoma. This study may help improve future treatments for this type of cancer.

High-Risk Diffuse Large B-Cell LymphomaLymphoma>2 yearsSafety phase (I)HematologyOncology

Capsaicin for Finger Pain in Osteoarthritis

We are studying whether a stronger capsaicin cream can reduce finger pain better than a lower dose in people with digital osteoarthritis. This trial also examines its effects on daily function and overall quality of life.

Finger Osteoarthritis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesRheumatology